Editing GSK plc (section)

===Malaria vaccine===
In 2014, GSK applied for regulatory approval for the first [[malaria vaccine]].<ref name="malariavaccine" /> [[Malaria]] is responsible for over 650,000 deaths annually, mainly in Africa.<ref>{{cite web |url=http://www.path.org/news/press-room/651/ |title=Press release: Malaria vaccine candidate reduces disease over 18 months of follow-up in late-stage study of more than 15,000 infants and young children |publisher=PATH |access-date=13 May 2014 |archive-date=15 April 2018 |archive-url=https://web.archive.org/web/20180415124827/http://www.path.org/news/press-room/651/ |url-status=live }}</ref> Known as [[RTS,S]], the vaccine was developed as a joint project with the [[PATH (global health organization)|PATH]] vaccines initiative and the [[Bill and Melinda Gates Foundation]]. The company has committed to making the vaccine available in developing countries for five per cent above the cost of production.<ref name=malariavaccine/>

{{As of|2013}}, RTS,S, which uses GSK's proprietary AS01 adjuvant, was being examined in a Phase 3 trial in eight African countries. PATH reported that "[i]n the 12-month period following vaccination, RTS,S conferred approximately 50% protection from clinical Plasmodium falciparum disease in children aged 5-17 months, and approximately 30% protection in children aged 6-12 weeks when administered in conjunction with Expanded Program for Immunization (EPI) vaccines."<ref>{{cite journal |vauthors=Birkett AJ, Moorthy VS, Loucq C, Chitnis CE, Kaslow DC |display-authors=3 |date=April 2013 |title=Malaria vaccine R&D in the Decade of Vaccines: breakthroughs, challenges and opportunities |journal=Vaccine |volume=31 |issue=Supplement 2 |pages=B233–43 |doi=10.1016/j.vaccine.2013.02.040 |pmid=23598488}}</ref> In 2014, Glaxo said it had spent more than US$350{{nbsp}}million and expected to spend an additional US$260{{nbsp}}million before seeking regulatory approval.<ref>{{cite web |url=http://www.gsk.com/media/press-releases/2013/malaria-vaccine-candidate-reduces-disease-over-18-months-of-foll.html |title=Malaria vaccine candidate reduces disease over 18 months of follow-up in late-stage study of more than 15,000 infants and young children |publisher=GlaxoSmithKline |url-status=dead |archive-url=https://web.archive.org/web/20140407081405/http://www.gsk.com/media/press-releases/2013/malaria-vaccine-candidate-reduces-disease-over-18-months-of-foll.html |archive-date=7 April 2014}}</ref><ref>{{cite news |last=McNeil |first=Donald G. Jr. |author-link=Donald G. McNeil Jr. |date=18 October 2011 |title=Scientists See Promise in Vaccine for Malaria |work=[[The New York Times]] |url=https://www.nytimes.com/2011/10/19/health/19malaria.html |url-status=live |archive-url=https://web.archive.org/web/20230405085414/https://www.nytimes.com/2011/10/19/health/19malaria.html |archive-date=5 April 2023}}</ref>